Can we quantify the quality of vision?

Article

The age of refractive surgery has introduced new aberrations to the human eye that require a shift in how visual performance is evaluated, said Ray Applegate, MD. Mesopic low contrast acuity best quantifies vision quality; it overcomes the weaknesses of other metrics and it can predict visual function among individuals.

The age of refractive surgery has introduced new aberrations to the human eye that require a shift in how visual performance is evaluated, said Ray Applegate, MD. Mesopic low contrast acuity best quantifies vision quality; it overcomes the weaknesses of other metrics and it can predict visual function among individuals.

Dr Applegate recruited 168 people with 6/6 or better vision across a range of ages and conducted a photopic high-contrast logMAR acuity test. "The test could only account for around 4% of the variation in our sample," he said. "We can't use it to predict the visual function of individuals. However mesopic low-contrast logMAR acuity accounted for a much broader range of the variation."

Dr Applegate said high contrast acuity is a poor metric because it is conducted under high luminance conditions and has excess contrast allowing a loss in contrast and image fidelity without a loss in measured acuity.

Contrast sensitivity, on the other hand, is impractical because it requires measurements along many different orientations. "That is simply not practical in the clinical environment and it is totally insensitive to phase shifts," insisted Applegate.

But mesopic low contrast acuity allows a large physiologic pupil and is sensitive to phase shifts and contrast loss. "It's also a recognition task as opposed to a detection task that's understood by clinicians and patients and it's easy to administer in a clinical setting," he said.

The study will be published shortly in Optometry and Vision Science.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.